Early markers for ALS study
Part of Brain & nervous system, Hormones & metabolism clinical trials.
This study looks for early signs of ALS in people with genetic risk, healthy controls, and people with early symptoms. It aims to find markers that could help diagnose ALS sooner.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 to 90 years old.
- You need to have health insurance through the French social security system.
- You must be able to give written informed consent.
- You cannot be pregnant.
- You need to be willing to provide blood, tear, and urine samples.
- You must be able to attend all scheduled visits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks for new ways to detect and understand ALS by analyzing tiny nerve and blood markers. It may help find better treatments for ALS and related nerve diseases.
This study aims to better understand ALS by looking at your genes, biomarkers, and stem cells. It may help develop treatments that are personalized to you.
This trial collects blood and spinal fluid samples from people being checked for ALS. The goal is to find clues (biomarkers) in tiny particles from nerve cells that could help doctors better understand and diagnose ALS.
This study collects a small skin sample (biopsy) from people with ALS, those who carry an ALS gene mutation but have no symptoms, and healthy volunteers. The sample is used to grow cells in the lab to better understand how ALS develops.
This study looks at blood platelets (tiny cells that help with clotting) in people with ALS and other motor neuron diseases. It aims to find new markers that could help diagnose ALS earlier. If you have a recent diagnosis, you may be able to join by giving a blood sample.
This study follows healthy people from families with a known ALS-causing gene mutation to look for early body or brain changes before symptoms begin. It may help researchers find ways to predict ALS risk earlier so future treatments can start sooner.
Hear when a new Amyotrophic Lateral Sclerosis (ALS) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.